Core Scientific (CORZ) Cash & Equivalents (2021 - 2026)

Core Scientific has disclosed Cash & Equivalents across 6 years of filings, most recently posting $1.0 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.0 billion, up 44.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 44.02% YoY), and the FY2025 annual result was $311.4 million, down 62.76% from the prior year.
• Cash & Equivalents came in at $1.0 billion for Q1 2026 at Core Scientific, up from $311.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.0 billion in Q1 2026 to a low of $15.9 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $98.1 million (2024), against an average of $282.4 million.
• Peak annual rise in Cash & Equivalents reached 6186.29% in 2022, while the deepest fall reached 86.52% in 2022.
• Core Scientific's Cash & Equivalents stood at $15.9 million in 2022, then jumped by 217.36% to $50.4 million in 2023, then jumped by 1558.83% to $836.2 million in 2024, then slumped by 62.76% to $311.4 million in 2025, then jumped by 222.81% to $1.0 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.0 billion (Q1 2026), $311.4 million (Q4 2025), and $453.4 million (Q3 2025), per Business Quant data.